BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8893202)

  • 1. A clinical correlative study of bone densitometric changes in hemodialysis patients with hyperparathyroidism.
    Adam B; Arik N; Başoğlu T; Akpolat T; Sahin M; Coşkun C; Kandemir T; Bernay I
    Nephron; 1996; 74(2):483-4. PubMed ID: 8893202
    [No Abstract]   [Full Text] [Related]  

  • 2. Secondary hyperparathyroidism in patients on maintenance hemodialysis: study of the N and C-terminal parathyroid hormones.
    Hida M; Shimbo T; Nakamura K; Wakabayashi T; Saitoh H; Satoh T
    Tokai J Exp Clin Med; 1983 Jul; 8(3):225-8. PubMed ID: 6670108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can successful renal transplantation resolve secondary hyper-parathyroidism?
    Koyama Y; Miyazato T; Hatano T; Ogawa Y
    Transplant Proc; 1996 Jun; 28(3):1644-5. PubMed ID: 8658819
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyperparathyroidism.
    Goldsmith RS
    N Engl J Med; 1969 Aug; 281(7):367-74. PubMed ID: 4893704
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
    Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
    Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No effect of vitamin K1 supplementation on biochemical bone markers in haemodialysis patients.
    Reichel H
    Nephrol Dial Transplant; 1999 Jan; 14(1):249-50. PubMed ID: 10052531
    [No Abstract]   [Full Text] [Related]  

  • 7. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.
    Zanchetta JR; Bogado CE
    J Bone Miner Res; 2001 Jan; 16(1):189-90. PubMed ID: 11149484
    [No Abstract]   [Full Text] [Related]  

  • 8. Physiological hyperparathyroidism in human lactation.
    Retallack RW; Jeffries M; Kent GN; Hitchcock NE; Gutteridge DH; Smith M
    Calcif Tissue Res; 1977 May; 22 Suppl():142-6. PubMed ID: 912515
    [No Abstract]   [Full Text] [Related]  

  • 9. Hyperparathyroidism with a prolonged period of normocalcemia.
    Johnson RD; Conn JW
    JAMA; 1969 Dec; 210(11):2063-6. PubMed ID: 5395208
    [No Abstract]   [Full Text] [Related]  

  • 10. Parathyroid function after kidney allografting.
    Tajima A; Ishikawa A; Ohta N; Suzuki K; Kawabe K; Aso Y
    Transplant Proc; 1996 Jun; 28(3):1629-30. PubMed ID: 8658814
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
    Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS;
    PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Famotidine reduces serum parathyroid hormone levels in uremic patients.
    Arik N; Arinsoy T; Sayín M; Taşdemir I; Yasavul U; Turgan C; Caglar S
    Nephron; 1991; 59(2):333. PubMed ID: 1956503
    [No Abstract]   [Full Text] [Related]  

  • 13. [Osteocalcin in chronic hemodialysis patients as an additional parameter in the diagnosis of advanced secondary hyperparathyroidism].
    Motz W
    Acta Med Austriaca; 1989; 16(1):8-12. PubMed ID: 2785325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term persistent hypocalcemia in a hemodialysis patient-- pathogenesis of secondary hyperparathyroidism].
    Kitoh C; Kurauchi K; Fujiwara R
    Nihon Jinzo Gakkai Shi; 1983 Aug; 25(8):1011-6. PubMed ID: 6668742
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of parathyroid levels and bone densitometry after cinacalcet treatment in severe primary hyperparathyroidism.
    Ogrin C
    Minerva Endocrinol; 2013 Sep; 38(3):337-8. PubMed ID: 24126554
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of phosphate-binders in patients on regular hemodialysis (author's transl)].
    Gahl G; Hopfenmüller W; Baethke R
    Med Klin; 1978 May; 73(19):710-4. PubMed ID: 651760
    [No Abstract]   [Full Text] [Related]  

  • 18. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study.
    Peacock M; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4860-7. PubMed ID: 19837909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of hyperparathyroidism in familial multiple endocrine adenomatosis type I (MEA I).
    Lamers CB; Froeling PG
    Am J Med; 1979 Mar; 66(3):422-4. PubMed ID: 34999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How many measurements to make a decision?
    Houillier P; Coste J; Froissart M
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1161-2. PubMed ID: 20558565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.